The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma.
Cong Xue
No relevant relationships to disclose
Qitao Yu
No relevant relationships to disclose
Jian-ji Pan
No relevant relationships to disclose
Yuanlu Sun
No relevant relationships to disclose
Li Zhang
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Research Funding - Lilly; Pfizer